Conversion to tacrolimus once-daily from ciclosporin in stable kidney transplant recipients: A multicenter study

Transplant International

Volumn 25, Issue 4, 2012, Pages 391-400

  Rostaing, Lionel ^a   Sánchez Fructuoso, Ana ^b   Franco, Antonio ^c   Glyda, MacIej ^d   Kuypers, Dirk R ^e   Jaray, Jenö ^f  

^a CHU RANGUEIL   (France)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d Szpital Wojewódzki ^*  (Poland)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

gingival hyperplasia; hirsutism; hyperlipidemia; kidney function; kidney transplantation; tacrolimus once daily

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; INSULIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; GINGIVA HYPERPLASIA; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; TREMOR;

ADULT; AGED; CREATININE; CYCLOSPORINE; FEMALE; GINGIVAL HYPERPLASIA; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TACROLIMUS;

EID: 84858442644     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01409.x     Document Type: Article

References (23)

1. Jevnikar A, Arlen D, Barrett B, et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Transplantation 2008; 86: 953.
2. Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF study. Transplantation 2008; 85: 1261.
3. Arzt MA, Boots JMM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880.
4. Arzt MA, Boots JMM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937.
5. Marcen R, Chahin J, Alarcon A, Bravo J,. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transpl Proc 2006; 38: 2427.
6. Margreiter R, Pohanka E, Sparacino V, et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl Int 2005; 18: 816.
7. Busque S, Demers P, St-Louis G, et al. Conversion from Neoral (ciclosporin) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc 1998; 30: 1247.
8. Thorp M, DeMattos A, Bennett W, Barry J, Norman D,. The effect of conversion from ciclosporin to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000; 69: 1218.
9. Woodside KJ, Nichols SD, Hunter GC, Gugliuzza KK, Daller JA,. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. Transplant Proc 2005; 37: 1877.
10. Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81: 1035.
11. Waid T,. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 2005; 19: 573.
12. Wlodarczyk Z, Squifflet J-P, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505.
13. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004; 77: 1199.
14. Ligtenberg G, Hené RJ, Blankestijn PJ, Koomans HA,. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368.
15. Pohanka E, Margreiter R, Sparacino V, Sperschneider H,. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. Transplant Proc 2005; 37: 1874.
16. O concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523.
17. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
18. Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
20. Ferriman DM, Gallwey JD,. Clinical assessment of body hair growth in women. J Clin Endocrinol 1961; 21: 1440.
21. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW,. Reporting of non-inferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 1152.
22. Krämer BK, Charpentier B, Tedesco Silva H, et al. Tacrolimus once daily (Advagraf) versus twice daily (Prograf) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632.
23. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648.